【摘要】 目的探讨CT引导下125I放射性粒子植入治疗腹膜后淋巴结转移癌的初步疗效。方法回顾性分析接受125I粒子植入治疗的18例腹膜后淋巴结转移癌患者共20个病灶,应用近距离治疗计划系统(TPS)制定治疗计划,粒子活度1.11×107~2.96×107Bq(0.3~0.8 m Ci),处方剂量60~110 Gy,CT引导下经皮、经肝植入粒子,术后验证D90(90%靶体积接受的剂量)53~107 Gy,评价患者临床受益反应(CBR)、2个月局部控制率、1年生存率,观察并发症情况。结果随访时间2~15个月,中位时间5个月;1年生存率22.2%。临床受益率72.2%,有效率70%,2个月局部控制率90%;所有患者均未出现严重并发症。结论 CT引导下125I粒子植入治疗腹膜后淋巴结转移癌近期疗效好,创伤小、并发症少,是一种相对安全的治疗方法。更多还原

【Abstract】 Objective To explore the clinical efficacy of CT-Guided radioactive125 I seed implantation in treating retroperitoneal lymph node metastases.Methods Eighteen patients with retroperitoneal lymph node metastases(20 lesions in total) received CT-guided radioactive125 I seed implantation.Treatment planning system(TPS) was used to formulate the therapeutic protocol.The radioactive activity of125 I particle ranged from 1.11 × 107-2.96 × 107Bq(0.3-0.8 m Ci) and the matched peripheral dose(MPD) was 60-100 Gy.Postoperative dosimetry was routinely performed for all the patients in one week.Postoperative D90(90%dose received by target volume) was 53-107 Gy.The patient’s clinical benefit response(CBR),two-month local tumor control rate and one-year survival rate were evaluated,and the complications were recorded.Results All the patients were followed up for 2-15 months with a median time of 5 months.The one-year survival rate was 22.2%.The clinical benefit rate,overall effective rate and two-month local tumor control rate were 72.2%,70.0% and 90.0% respectively.No serious complications occurred in all patients.Conclusion For the treatment of retroperitoneal lymph node metastases,CT-guided radioactive125 I seed implantation is mini-invasive with satisfactory short-term effect and fewer complications.Therefore,this technique is a relatively safe therapeutic means.更多还原